Adicet Bio, Inc.
Adicet Bio
200 Constitution Drive
Menlo Park
California
94025
United States
Website: http://www.adicetbio.com/
About Adicet Bio, Inc.
Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors. Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and then generating T Cell Receptor-like monoclonal antibodies (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs are being used to arm T cells or as T cell engagers in solid tumors. In August 2016, Adicet entered into a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology.
For more information, please visit our website at http://www.adicetbio.com.
112 articles about Adicet Bio, Inc.
-
Adicet Bio to Participate in Upcoming Investor Conferences - Apr 07, 2022
4/7/2022
Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor T cell therapies for cancer, announced that company management will participate in two upcoming investor conferences in April.
-
Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/1/2022
Adicet Bio, Inc. today announced it granted inducement awards on March 31, 2022 (the “Grant Date”) under Adicet’s 2022 Inducement Plan as a material inducement to employment to two individuals hired by Adicet in March 2022.
-
Adicet Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
3/15/2022
Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor T cell therapies for cancer, reported financial results and operational highlights for the fourth quarter and year ended December 31, 2021.
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Mar 04, 2022
3/4/2022
Adicet Bio, Inc. announced it granted inducement awards on February 28, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to three individuals hired by Adicet in February 2022.
-
BioSpace Movers & Shakers, Feb. 18
2/18/2022
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Adicet Bio to Participate in Guggenheim 2022 Oncology Conference
2/2/2022
Adicet Bio, Inc. announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2022 Oncology Conference taking place virtually on February 9-11, 2022.
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
Innocoll Biotherapeutics, Genapsys, and Adicet Bio announced today their relocation and expansion plans. -
Adicet Bio, Inc. Announces Closing of $100 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
12/10/2021
Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced the closing of its previously announced underwritten public offering of 7,187,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 937,500 shares of common stock.
-
Adicet Bio, Inc. Announces Pricing of Public Offering of Common Stock - Dec 08, 2021
12/8/2021
Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $14.00 per share.
-
Adicet Bio, Inc. Announces Proposed Follow-On Offering of Common Stock - Dec 07, 2021
12/7/2021
Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, announced that it has commenced an underwritten public offering of its common stock.
-
ADI-001 generated positive early responses from three of four evaluable participants, two of whom achieved complete responses while one had a partial response that researchers logged as "near complete." -
Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy
12/6/2021
Adicet Bio, Inc. (Nasdaq: ACET), today announced positive interim data from its dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001, Adicet’s investigational therapy targeting CD20 for the potential treatment of B-cell Non-Hodgkin’s Lymphoma.
-
Adicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data in B Cell Non-Hodgkin’s Lymphoma
11/29/2021
Adicet Bio, Inc. today announced that the Company will host a webcast presentation on Monday, December 6, 2021.
-
Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors
11/18/2021
Adicet Bio, Inc. today announced the appointment of Michael G. Kauffman, M.D., Ph.D., to its Board of Directors.
-
Adicet Presents Preclinical Data for ADI-002, a GPC3-Targeted Development Candidate for Solid Tumors, at the SITC Annual Meeting
11/12/2021
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the presentation of new preclinical data supporting its Glypican-3 (GPC3) targeted allogeneic, off-the-shelf gamma delta chimeric antigen receptor (CAR) T cell development candidate for solid tumors at the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting.
-
Adicet Reports Third Quarter 2021 Financial Results and Provides Business Updates
11/10/2021
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today reported operational highlights and financial results for the third quarter ended September 30, 2021.
-
Adicet Bio to Participate in Stifel 2021 Virtual Healthcare Conference
11/8/2021
Adicet Bio, Inc. today announced that Chen Schor, President and Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference taking place on November 15-17, 2021.
-
Adicet Announces Trials in Progress Poster Presentation for ADI-001 at 2021 ASH Annual Meeting
11/4/2021
Adicet Bio, Inc., a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, announced that a Trials in Progress abstract related to the Company’s lead candidate, ADI-001, has been accepted for an oral presentation at the 63rd American Society of Hematology Annual Meeting and Exposition being held December 11-14, 2021.
-
Adicet Announces Promotion of Blake Aftab, Ph.D. to Chief Scientific Officer
10/12/2021
Adicet Bio, Inc., a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, announced Blake Aftab, Ph.D., has been promoted to the position of Senior Vice President and Chief Scientific Officer.